Moberg Pharma has granted the exclusive rights to market and sell Emtrix in Russia and Ukraine to Berlin-Chemie, a member of the Menarini Group. The extended distribution agreement builds on an existing collaboration between Moberg and Menarini, which resulted in a successful launch of Emtrix in Italy and most recently, the expansion to China and Southeast Asia where product launches have been initiated. The rights to Emtrix in Russia were released from a previous distribution agreement with Meda. The product was not launched in Russia under the previous agreement.

Emtrix is a topical treatment used to treat nail disease. Launched in late 2010, it quickly became the market leader in the Nordics and recently also the best-selling product in its category in the U.S.

Berlin-Chemie/Menarini is a leading regional biopharmaceutical company with full national coverage in Russia, a sales force with more than 700 sales representatives and a strong track record of launching and promoting Consumer Health brands. The global sales of the Menarini Group exceed 3.3 billion Euros. Russia and Ukraine comprise almost 200 million people and represent a significant long-term growth opportunity for Moberg Pharma.